(1)Dept of Surgical Oncology, Erasmus MC-University Medical Center, Rotterdam, Netherlands. (2)Dept of Medical Oncology, Erasmus MC-University Medical Center, Rotterdam, Netherlands. (3)Dept of Gastroenterology and Hepatology, Erasmus MC-University Medical Center, Rotterdam, Netherlands.
Publication
Front Onc
Summary
Recently, targeted therapies are being explored in desmoid-type fibromatosis (DTF). Unfortunately, effective treatment is still hampered by the limited knowledge of the molecular mechanisms that prompt DTF tumorigenesis. Many studies focus on Wnt/beta-catenin signaling, since the vast majority of DTF tumors harbor a mutation in the CTNNB1 gene or the APC gene. The established role of the Wnt/beta-catenin pathway in DTF forms an attractive therapeutic target, however, drugs targeting this pathway are still in an experimental stage and not yet available in the clinic. Only few studies address other signaling pathways which can drive uncontrolled growth in DTF such as: JAK/STAT, Notch, PI3 kinase/AKT, mTOR, Hedgehog, and the estrogen growth regulatory pathways. Evidence for involvement of these pathways in DTF tumorigenesis is limited and predominantly based on the expression levels of key pathway genes, or on observed clinical responses after targeted treatment. No clear driver role for these pathways in DTF has been identified, and a rationale for clinical studies is often lacking. In this review, we highlight common signaling pathways active in DTF and provide an up-to-date overview of their therapeutic potential.
Stay Up to Date as We Uncover More About Desmoid Tumors
